Stock screener

MYGN

Conviction 53HealthcareScan · Thu, Jun 25, 2026
MYGN$5.42+3.74%
ResistanceSupportVol 14Insider buyInsider sell
63 bars
Vol MA14 1.49M
Mar 26Apr 14May 1May 19Jun 8Jun 25
MYRIAD GENETICS INCIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.myriad.com
Price5.42
Change+3.74%
Gap+0.77%
Rel volume1.77×
Avg volume1.84M
Avg $ vol8.25M
SMA 204.50
SMA 504.44
SMA 2005.83
Price vs 50+21.87%
Price vs 200-7.08%
MA stackmixed
50/200 cross
Supertrendup · 4.44
RSI (14)70
MACD hist0.10
MACD cross
Stoch %K / %D93 / 89
ADX (14)24
+DI / −DI37 / 10
RSI divergence
MACD divergence
ATR %+5.62%
ADR %7.07%
52w high8.18
52w low3.55
From 52w high-33.80%
Above 52w low+52.54%
New 52w highNo
SqueezeOff
Bollinger width28.40%
%B1.22
Donchian pos94.24%
Donchian high5.51
Donchian low3.86
AVWAP (52w high)5.26
vs AVWAP high+2.95%
AVWAP (52w low)4.33
vs AVWAP low+24.96%
OBV trendUp
Chaikin MF (20)0.10
Today vs 20d1.77×
Avg vol (14d)1.49M
Avg vol (20d)1.84M
Avg $ vol (20d)8.25M
Market cap511.44M
RS 3m (vs SPY)+0.98%
RS 6m (vs SPY)-28.04%
RS line new highNo
Trend template3/8
Technical rank51.6
1 week+23.63%
1 month+40.65%
3 months+15.71%
6 months-19.90%
1 year+7.23%
YTD-11.81%
P/E-1.40
P/B1.52
P/S0.62
P/FCF-11.76
EPS-3.95
Div yield
ROE-108.45%
ROA-54.31%
Debt/Eq0.53
Current2.40
EV/EBITDA-1.50
Gross margin69.93%
Net margin-44.38%
Rev growth-1.56%
EPS growth-187.43%
Price target7.50
Target upside38.50%
Analyst ratingBuy
Institutional105.23%
Ent. value566.74M
Revenue200.4M
Net income-34.1M
Gross profit137.6M
Free cash flow-43.5M
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
ExchangeNasdaq
Shares out94.45M
Employees2.7K
ListedFri, Oct 6, 1995
Free float89.75M
Float %96.0%
Short interest8.55M
Days to cover4.2d
Short volume30.1%
Squeeze score52 / 100
Next earningsTue, Aug 4, 2026 (40d)
EPS forecast−$0.08 · 1 est
Last EPS vs est−$0.16 vs −$0.16
Last surprise0.0% beat
Setup gradeC
Conviction53 / 100
Pattern quality
Tech rank51.6 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance4.92
Support3.64
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in MYGN

All disclosures →
No recent disclosed trades by Congress in MYGN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in MYGN · 9 buys · 1 sell

InsiderSideShares
Kumar Rashmi
Director · Common Stock · 2026-06-08
Sell15K
Dreismann Heinrich
Director · Common Stock · 2026-06-04
Grant59.7K
Bisaro Paul
Director · Common Stock · 2026-06-04
Grant59.7K
Newcomer Lee Nisley
Director · Common Stock · 2026-06-04
Grant59.7K
Davis Mark Steven
Director · Common Stock · 2026-06-04
Grant59.7K
Phanstiel S. Louise
Director · Common Stock · 2026-06-04
Grant59.7K
Kumar Rashmi
Director · Common Stock · 2026-06-04
Grant59.7K
Reitan Colleen F
Director · Common Stock · 2026-06-04
Grant59.7K
Skovronsky Daniel
Director · Common Stock · 2026-06-04
Grant59.7K
Jampa Raj
Chief Technology Officer · Common Stock · 2026-06-01
Grant251.89K

SEC filings

EDGAR filings in MYGN · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.